The last decade or two have witnessed a plethora of newer chemotherapy drugs being approved for treating cancer, most of which have been approved based on clinical trials using the RECIST 1.1 (or the older RECIST) criteria to demonstrate efficacy of treatment and prolongation of disease-free survival. However, how accurate are the RECIST 1.1 criteria actually in assessing tumor response? A recent article in Radiology answers this question, and shows that there is still a lot of scope for improvement. I believe that the RECIST 1.2 criteria do not seem far away. We discuss the article in Journal Watch.

You can read the entire Radiology article here.

– Akshay Baheti, Tata Memorial Hospital

PS : If the embedded video is not opening, you can view the video on YouTube by clicking here.